Clin Oncol | Volume 8, Issue 1 | Research Article | Open Access
Yu H1#, Wang R1#, Gao Y1#, Zhang J1, Gao J1, Lu F1, Chen Z1, Xia Y1, Hou Y1, Li L1, Wang L1, Moreira P2,3*, Chang L1* and Li W1*
1Department of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University, China
2International Healthcare Management Research and Development Centre, Shandong First Medical University, China
3Department of Biology, Medicine and Health, The University of Manchester, UK
#These authors contributed equally to this work
*Correspondance to: [email protected]Fulltext PDF
Evidence on the anti-cancer effect of high-dose Ascorbic Acid (AA) has been generated from several basic and clinical studies. AA can increase the level of Reactive Oxygen Species (ROS) through oxidative stress, modulate tumor immunity. However, a model using “continually intravenous pump of AA for 24 h” has not been widely reported. We treated 4 palliative patients using this approach combining the metabolic mechanisms of AA in the body and possible synergy mechanisms with arginine and magnesium ion. The results show significantly improved survival in two patients with advanced Lung Adenocarcinoma (LUAD) who received this combination therapy and no serious adverse events occurring. Therefore, we explored a high-dose AA combination with arginine and magnesium sulfate with exhibited synergistic anti-tumor effects in LUAD, which have significantly improved anti-cancer effects and enhance anti-tumor immunity in vitro and in vivo. This study provides a contribution to a debate on a new high-efficiency and low-toxicity combination therapy in future clinical practice, potentially improving the prognosis of patients with LUAD.
Graphical Abstract: Image 1.
Ascorbic acid; Arginine; Magnesium sulfate; Lung adenocarcinoma; ROS; Antitumor immunity
Yu H, Wang R, Gao Y, Zhang J, Gao J, Lu F, et al. Inducing Anti-Tumor Immune Responses in Lung Adenocarcinoma: High-Dose of Ascorbic Acid Combined with Arginine and Magnesium Sulfate. Clin Oncol. 2023;8:1994..